Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

4(44.4%)

Phase 1

3(33.3%)

Phase 3

2(22.2%)

9Total

Phase 2(4)

Phase 1(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02467582Phase 3Terminated

Adjuvant Aspirin Treatment for Colon Cancer Patients

Role: collaborator

NCT03227016Phase 1Unknown

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Role: lead

NCT00806663Phase 2Completed

FOLFIRI and Sunitinib in Metastatic Colorectal Cancer

Role: lead

NCT01731158Phase 2Completed

Sequential Therapy in Metastatic Renal Cell Carinoma

Role: lead

NCT01326767Phase 3Completed

Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring

Role: lead

NCT01206036Phase 1Completed

CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)

Role: lead

NCT00979966Phase 2Completed

Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib

Role: lead

NCT00673504Phase 2Completed

First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer

Role: lead

NCT01259518Phase 1Unknown

Dose Escalation Study of TriN2755 in Advanced Solid Tumors and Sarcomas

Role: collaborator

All 9 trials loaded